United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 43,025 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $111.11, for a total value of $4,780,507.75. Following the completion of the sale, the chief executive officer now owns 21,652 shares of the company’s stock, valued at $2,405,753.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Co. (NASDAQ UTHR) traded up $0.14 during midday trading on Friday, hitting $111.14. 613,296 shares of the stock traded hands, compared to its average volume of 461,033. The firm has a market capitalization of $4,837.66, a price-to-earnings ratio of 11.90 and a beta of 1.32. The company has a current ratio of 3.26, a quick ratio of 3.01 and a debt-to-equity ratio of 0.12. United Therapeutics Co. has a 12 month low of $107.82 and a 12 month high of $152.55.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.59 by $0.30. The company had revenue of $464.70 million during the quarter, compared to analyst estimates of $420.55 million. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The company’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the business posted $4.12 earnings per share. research analysts expect that United Therapeutics Co. will post 12.46 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Wedge Capital Management L L P NC raised its holdings in shares of United Therapeutics by 2,725.8% during the fourth quarter. Wedge Capital Management L L P NC now owns 324,631 shares of the biotechnology company’s stock worth $48,029,000 after acquiring an additional 313,143 shares during the period. Renaissance Technologies LLC increased its stake in United Therapeutics by 14.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,462,378 shares of the biotechnology company’s stock valued at $216,359,000 after buying an additional 189,378 shares during the last quarter. JPMorgan Chase & Co. increased its stake in United Therapeutics by 28.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 640,475 shares of the biotechnology company’s stock valued at $76,065,000 after buying an additional 139,976 shares during the last quarter. LSV Asset Management increased its stake in United Therapeutics by 59.8% in the 4th quarter. LSV Asset Management now owns 274,146 shares of the biotechnology company’s stock valued at $40,559,000 after buying an additional 102,565 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in United Therapeutics by 9.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 798,093 shares of the biotechnology company’s stock valued at $93,531,000 after buying an additional 71,333 shares during the last quarter.
A number of equities research analysts have weighed in on UTHR shares. Barclays restated an “underweight” rating and issued a $105.00 target price (down from $115.00) on shares of United Therapeutics in a research report on Thursday, February 22nd. Credit Suisse Group restated an “underperform” rating and issued a $115.00 target price (down from $120.00) on shares of United Therapeutics in a research report on Thursday, February 22nd. ValuEngine cut United Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. Finally, BidaskClub downgraded shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 24th. Five research analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $135.20.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 43,025 Shares of Stock” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/16/insider-selling-united-therapeutics-co-uthr-ceo-sells-43025-shares-of-stock.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.